Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and hybrid continuous purification technologies. Under the deal Transcenta will receive upfront, milestone and royalty payments; EirGenix will deploy HiCB to serve CDMO clients seeking intensified manufacturing solutions. Transcenta and EirGenix emphasized the deal’s potential to lower biologics cost and expand global access. The agreement also transfers regulatory support packages and process documentation, signaling an industry trend toward licensing of intensified continuous platforms to scale biologics production more efficiently.